Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia

References

• Hahn RA, Heath GW, Chang MH. Cardiovascular disease risk factors and preventive practices among adults — United States, 1994: a behavioral risk factor atlas. Behavioral risk factor surveillance system state co-ordinators. Morbidity & Mortality Wekly Report. CDC Surveillance Summaries 47(5), 35–69 (1998).
   Google Scholar
• LaRosa JC, Hunninghake D, Bush D et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Circulation 872, 1721–1733 (1990).
   Google Scholar
• Pekkaneh J, Linn S, Heiss G eta]. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 324(1), 60–61 (1991).
   Google Scholar
• Scott R. Lipid modifying agents: mechanisms of action and reduction of cardiovascular disease. Clin. Exp. Pbarmacol Plysiol 24(5), A26—A28 (1997).
   Google Scholar
• Plans-Rubio P Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Pub. Health 111, 33–40 (1997).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Gonzalez ER. Preventing cardiovascular athlerosderosis: Role of HMG-CoA inhibitors. Formulary31, 582–602 (1996).
   Google Scholar
• Bradley CA, Iskedjian M, Lancot KL et al Quality assessment of economic evaluations in selected pharmacy, medical and health economics journals. Ann. Pbarmacother. 29, 681–689 (1995).
   PubMedGoogle Scholar
• ••Excellent overview of application ofquality assessment of economic evaluations.
   Google Scholar
• Iskedjian M, Traikas K, Bradley CA et al Quality assessment of economic evaluations published in pharmacoeconomics. PbarmacoEconomics 12,685–694 (1997).
   PubMedGoogle Scholar
• Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilimtion of a checklist. Ann. Pbarmacother. 27,1126-1133 (1993).
   Google Scholar
• ••Initial publication of the qualityassessment checklist.
   Google Scholar
• ISPOR Lexicon. 1: 18. Pashos CL, Klein EG, Wanke LA (Eds).
   Google Scholar
• Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JA/VIA 258(17), 2381–2387 (1987).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Kinosian BP, Eisenberg JM. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA 259(15), 2249–2254 (1988).
   PubMed Web of Science ®Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Martens LL, Rutten FF, Erkelens DW et a/. Cost-effectiveness of cholesterol-lowering therapy in the Netherlands. Simvastatin versus cholestyramine. Am J Med. 87(4A), 54S-58S (1989).
   Google Scholar
• Martens LL, Rut-ten FF, Erkelson DVV, Ascoop CA. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am. J Candiol. 65,27f-32f (1990).
   Google Scholar
• Goldman L, Weinstein MC, Goldman PA, Williams LW Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265(9), 1145–1151 (1991).
   PubMed Web of Science ®Google Scholar
• Hay JW, Wittels EH, Gott° AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am. J Candid 67(9), 789–796 (1991).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Kristiansen IS, Eggen AE, Thelle DS. Cost- effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worthwhile? Br. Med. 302,1119–1122 (1991).
   Google Scholar
• Hjalte K, Lindgren B, Persson U. Cost- effectiveness of simvastatin versus cholestyramine. PhannacoEconomics1 (3), 213–216 (1992).
   PubMedGoogle Scholar
• Goldman L, Goldman PA, Williams LW Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am. J Carrliol. 72,75D-79D (1993).
   Google Scholar
• Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Cl/n. Ther. 16(6), 1052–1062 (1994).
   Google Scholar
• Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL- C. JA/V/A 273(13), 1032–1038 (1995).
   Google Scholar
• Ashraf T, Hay JW, Pitt B et al. Cost- effectiveness of pravastatin in secondary prevention of coronary artery disease. Am. Carrliol. 78,409–414 (1996).
   PubMedGoogle Scholar
• Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian simvastatin survival study (4S). Ear Hear t 117, 1001–1007 (1996).
   Google Scholar
• Johannesson M, Borgquist L, Jonsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary healthcare. J Lit. Med 240,23–29 (1996).
   Google Scholar
• Perrault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost-effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Carrliovasc. Drugs Ther: 10,787–794 (1996).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Pharoah PD, Hollingworth W Cost- effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Br. Med J 312, 1443–1448 (1996).
   PubMed Web of Science ®Google Scholar
• Caro J, Klittich W McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br. Med. J 315,1577–1582 (1997).
   Google Scholar
• Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl. J Med 336(5), 332–336 (1997).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Riviere M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Can. Med Assoc. 156(7), 991–997 (1997).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Huse DM, Russel MW, Miller JD et al. Cost-effectiveness of statins. Am J 82,1357–1363 (1998).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Muls E, Van Ganse E, Closon MC. Cost- effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclemsis 137(Suppl.), S111—S116 (1998).
   Google Scholar
• Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher doses of lovastatin cost-effective? Arrh. Intern. Med 158,375–381 (1998).
   PubMedGoogle Scholar
• •Article achieving high assessment score.
   Google Scholar
• Plans-Rubio P. Cost-effectiveness of cardiovascular prevention programs in Spain. J. Tech. Assess. Healthcare 14(2), 320–330 (1998).
   Google Scholar
• Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart 19 (Suppl. C), C59—C65 (1998).
   Google Scholar
• Elliott W Weir D. Comparative cost- effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am. J Health-Syst. Pharm. 56,1726-1732 (1999).
   Google Scholar
• Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease. Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arrh. Intern. Med 159,593–600 (1999).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Pickin DM, McCabe CJ, Ramsay LE eta]. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 82 (3), 325–332 (1999).
   PubMed Web of Science ®Google Scholar
• Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor therapy in older patients with myocarclial infarction. Ann. Intern. Med. 132(10), 780–787 (2000).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Prosser LA, Stinnet AA, Goldman PA eta]. Cost-effectiveness of cholesterol lowering therapies according to selected patient characteristics. Ann. Intern. Med 132(10), 769–779 (2000).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Sarma S, Fifer SK. Gemfibrozli cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. Drugs 40\(Suppl. 1), 42–52 (1990).
   Google Scholar
• Schulman KA, Kinosian B, Jacobson TA et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 264(23), 3025–3033 (1990).
   PubMed Web of Science ®Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Lim MC, Foo WM. Efficacy and cost- effectiveness of simvastatin and gemfibrozli in the treatment of hyperlipidaemia. Ann. Acad. Med. 21(1), 34–37 (1992).
   Google Scholar
• Kinlay S, O'Connell D, Evans D, Halliday J. The cost-effectiveness of different blood-cholesterol-lowering strategies in the prevention of coronary heart disease. Aust. J. Pub. Health 18(1), 105–110 (1994).
   Google Scholar
• Smart AJ, Walters L. Pharmacoeconomic assessment of the HMG-CoA reductase inhibitors. S Ah: Med J 84,834–837 (1994).
   PubMed Web of Science ®Google Scholar
• McGehee MM, Johnson EQ, Rasmussen HM, Sahyoun N, Lynch MM, Carey M. Benefits and costs of medical nutrition therapy by registered dietitians for patients with hypercholesterolemia. jAm. Diet Assoc. 95(9), 1041–1043 (1995).
   PubMedGoogle Scholar
• Schrott HG, Stein EA, Dujovne CA eta]. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am. J Carrliol. 75, 34–39 (1995).
   Google Scholar
• Tomson Y, Johannesson M, Aberg H. The costs and effects of two different lipid intervention programmes in primary healthcare. J. Intern Med. 237(1), 13–17 (1995).
   Google Scholar
• Oster G, Borok GM, Menzin J et at Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arrb. bit. Med. 156,731–739 (1996).
   Google Scholar
• Brannon SD, Tershakovec AM, Shannon BM. The cost-effectiveness of alternative methods of nutritional education for hypercholesterolemic children. Am. J. Public Health 87(12), 1967-1970 (1997).
   Google Scholar
• •Article achieving high assessment score.
   Google Scholar
• Ito MK, Shabetai R. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Am.j Cardiol 80,799–802 (1997).
   PubMedGoogle Scholar
• Kirchgassler KU, Schiffner-Rohe J, Stahlheber U. Cost effectiveness of miconised fenofibrate and simvastatin in the short-term treatment of Type IIa and Type IIb hyperlipidaemia. PbarmacoEconomics 12(2 Pt 2), 237–246 (1997).
   Google Scholar
• Spearman ME, Summers K, Moore V, Jacqmin R, Smith G, Groshen S. Cost-effectiveness of initial therapy with 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed care organization. Clin. filer. 19(3), 582–602 (1997).
   Google Scholar
• Koren MJ, Smith DG, Hunninghake DB et al The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. PbarmacoEconomics14(1), 59–70 (1998).
   PubMedGoogle Scholar
• Naglak M, Mitchell DC, Kris-Etherton P, Harkness W Pearson TA. What to consider when conducting a cost-effectiveness analysis in a clinical setting. jAm. Diet Assoc. 98(10), 1149–1154 (1998).
   Google Scholar
• Pederson TR. Coronary artery disease: the Scandinavian simvastatin survival study experience. Am.j Cardiol 82 (10B), 53T-56T (1998).
   Google Scholar
• Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versusatorvastatin: results of the surrogate marker cost-efficacy (SmaC) study. Clin. filer. 21(10), 1788–1796 (1999).
   Google Scholar
• Cobos A, Jovell AJ, Garcia-Altes A, Garcia- Closas R, Serra-Majem L. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis. Clin. filer. 21(11), 1924–1936 (1999).
   Google Scholar
• Hilleman DE, Woodruff MP, Holmberg MJ, VVurdeman RL, Ryschon KL, Seyedroudbari A. Comparative cost-effectiveness of fluvastatin and lovastatin in patients with hypercholesterolemia. Managed Care Pbarm. 6(3), 241–246 (2000).
   Google Scholar
• Sikand G, Kashyap ML, Wong ND, Hsu JC. Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance. jAm. Diet Assoc. 100 (2), 218–224 (2000).
   PubMedGoogle Scholar
• Oster G, Borok GM, Menzin J et al. A randomized trial to assess the effectiveness and cost in clinical practice: Rationale and design of the cholesterol reduction intervention study (CRIS). Control Clin. Trials 16,3–16 (1995).
   PubMedGoogle Scholar
• Tolman KG. The liver and lovastatin. Am. Cardiol 15;89(12), 1374–1380 (2002).
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Panel on Cost Effectiveness in Health and Medicine. Appendix A: Summary Recommendations. In: Cost Effectiveness in Health and Medicine. Oxford University Press, New York, USA, 304–311 (1996).
   Google Scholar
• ••Key text for guidelines and summaryrecommendations for health economic research.
   Google Scholar
• Morris S. A comparison of economic modeling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 6 (6), 589–601 (1997).
   Google Scholar
• Drummond ME, Davies L. Economic analysis alongside clinical trials. Int. J. Technol Assessment in Healthcare7, 561–573 (1991).
   PubMedGoogle Scholar